Western Blot: 1/500 - 1/1000. Immunohistochemistry: 1/50 - 1/200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Activation of TAL1 characterizes up to 60 % of cases of human T cell acute lymphoblastic leukemia, making it the most frequent gain-of-function mutation observed in this disorder. TAL1 (also designated SCL) is a serine phosphoprotein and basic helix-loop-helix transcription factor known to regulate embryonic hematopoiesis. This transcription factor binds as a heterodimer with E2A and HEB/HTF4 to a nucleotide sequence motif termed the E-box. In addition, leukemogenesis is accelerated dramatically by transgenic co-expression of TAL1 and the catalytic subunit of casein kinase IIalpha, a serine/ threonine protein kinase known to modulate the activity of other bHLH transcription factors.Synonyms: SCL, Stem cell protein, T-cell acute lymphocytic leukemia protein 1, T-cell leukemia/lymphoma protein 5, TAL-1, TCL5